Is Low-Dose Thrombolysis for Acute Ischemic Stroke a Viable Option?

Low-dose therapy was not noninferior in the ENCHANTED trial.

Epidemiologic studies have shown that Asians have an increased risk for hemorrhagic stroke compared with white patients. This pattern has led to concerns about the safety of full-dose IV tissue plasminogen activator (TPA) in Asian patients with acute ischemic stroke. In Japan, a reduced dose of TPA (0.6 mg/kg) has been approved instead of the conventional dose (0.9 mg/kg). The current study was a randomized trial of these two doses of TPA in 3310 patients with acute ischemic stroke. The patients were predominantly Asian (63%); median age was 67.5 years. Participants had milder presenting strokes than in earlier trials (median NIH stroke scale score, 8–9) and were treated later (average, 170 minutes after stroke onset). The primary outcome w…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Is Low-Dose Thrombolysis for Acute Ischemic Stroke a Viable Option?

Topics

Reviewing Author